Measles vaccine coverage and immune response in children of Caiabi and Metuktire Indian tribes living in malarial endemic area: Parque indígena do Xingu, Central Brazil.
Measles vaccination efficiency was evaluated in children from two Indian tribes - Caiabi and Metuktire - living in the Amazon region, in the Parque Indigena do Xingu (PIX). The population sample, selected at random, made up 37 Caiabi and 28 Metuktire children, aged from 20-75 months (40%). For operational and epidemiological reasons, measles vaccine is given from 6 months of age. The average age of children when they received the vaccine was 11.5 months for the first dose and 20 months for the second. The search for IgG antibodies against measles virus and Plasmodium falciparum was made through immunofluorescence assay (IFA). Measles vaccine coverage has reached 60% at 12 months of age and 92% at 18 months, whereas post-vaccine serum conversion was 95% in Caiabi children (geometric mean of titres (GMT) 126) and 89% in Metuktire (GMT 109). The difference in GMT is not statistically significant. Seventy-three per cent of Caiabi children (GMT 101) and 100% of Metuktire children (GMT135) were plasmodium antibody positive, showing they had been exposed to malarial infection. Despite the differences detected, the immune response to measles vaccine was satisfactory in both groups, with a positive percentage consistent with that achieved in non-malarial areas in Americas. The results show the efficiency of a vaccination programme in an indigenous area despite the difficulties in reaching the villages and maintaining the cold chain, and also despite the malaria endemicity.
Spindel
R
R
Departamento de Medicina Preventiva, UNIFESP/Escola Paulista de Medicina, São Paulo, Brazil.
Baruzzi
R G
RG
Souza
V A
VA
Ferreira
A W
AW
Avila
S L
SL
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood*; D001938:Brazil / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007199:Indians, South American / Q000706:statistics & numerical data*; D007223:Infant; D016778:Malaria, Falciparum / Q000453:epidemiology; D008297:Male; D008457:Measles / Q000453:epidemiology* / Q000517:prevention & control*; D008458:Measles Vaccine; D008459:Measles virus / Q000276:immunology*; D017063:Outcome Assessment, Health Care; D010963:Plasmodium falciparum / Q000276:immunology; D011314:Preventive Health Services / Q000592:standards*
D000913:Antibodies, Protozoan; D000914:Antibodies, Viral; D008458:Measles Vaccine